CytoMed Therapeutics Pte. Ltd. (CIK: 0001873093) EDGAR, Information, Filings... CompaniesBIO.Com

CytoMed Therapeutics Pte. Ltd.

Mailing address
21 BUKIT BATOK CRESCENT, #17-80 WCEGA TOWER, JURONG EAST, Singapore, 75248
Phone
603824911
State location
Texas
State of incorporation
Singapore
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

CytoMed Therapeutics Pte. Ltd. (CIK: 0001873093) is an American company incorporated in the state of Texas. Head office is located at 21 BUKIT BATOK CRESCENT, #17-80 WCEGA TOWER, JURONG EAST, Texas, 75248. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. CytoMed Therapeutics Pte. Ltd. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Choo Chee Kong	0001970632	Mar-31-2023	director, 10 percent owner
Zeng Jieming	0001970819	Mar-31-2023	director, officer: CSO and CMO
Wang Shu	0001972300	Mar-31-2023	10 percent owner
Tan Wee Kiat	0001973162	Mar-31-2023	director, officer: Chief Operating Officer
Toh Keng Kiat	0001973295	Mar-31-2023	director
Glorious Finance Ltd	0001973345	Mar-31-2023	10 percent owner
Luk Lucas Tien Wee	0001973388	Mar-31-2023	director, officer: Chief Clinical Officer
Leong Mark Kei Wei	0001973389	Mar-31-2023	director
Yew Chak Hua	0001973390	Mar-31-2023	director
Loh Yuin Han	0001973540	Mar-31-2023	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by CytoMed Therapeutics Pte. Ltd.

Filings	Format	Description	Filed/Effective	File/Film Number
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-048899 (34 Act) Size: KB	Dec-05-2024	001-41677 241529792
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-046929 (34 Act) Size: KB	Nov-20-2024	001-41677 241478258
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001973616-24-000001 (33 Act) Size: 0 KB	Nov-04-2024	001-41677 241421839
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-039643 (34 Act) Size: KB	Oct-07-2024	001-41677 241356173
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-039293 (34 Act) Size: KB	Oct-03-2024	001-41677 241349879
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-038680 (34 Act) Size: KB	Sep-30-2024	001-41677 241336625
6-K/A	Document	Amendment to Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-024921 (34 Act) Size: KB	Jun-24-2024	001-41677 241063568
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-024464 (34 Act) Size: KB	Jun-20-2024	001-41677 241055352
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-021281 (34 Act) Size: KB	May-24-2024	001-41677 24982162
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001493152-24-021087 (34 Act) Size: KB	May-23-2024	005-94045 24975127
6-K/A	Document	Amendment to Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-015906 (34 Act) Size: KB	Apr-25-2024	001-41677 24875786
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-015796 (34 Act) Size: KB	Apr-24-2024	001-41677 24870741
20-F	Document	Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Acc-no: 0001493152-24-015594 (34 Act) Size: KB	Apr-22-2024	001-41677 24862094
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-010173 (34 Act) Size: KB	Mar-18-2024	001-41677 24756816
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-008640 (34 Act) Size: KB	Mar-04-2024	001-41677 24712770
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001493152-24-006597 (34 Act) Size: KB	Feb-14-2024	005-94045 24637400
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001493152-24-006596 (34 Act) Size: KB	Feb-14-2024	005-94045 24637399
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001493152-24-006595 (34 Act) Size: KB	Feb-14-2024	005-94045 24637401
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001493152-24-006594 (34 Act) Size: KB	Feb-14-2024	005-94045 24637403
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001493152-24-004055 (34 Act) Size: KB	Jan-29-2024	001-41677 24570047

Recent 20 filings. View all CytoMed Therapeutics Pte. Ltd. filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

CytoMed Therapeutics Pte. Ltd. overview
CytoMed Therapeutics Pte. Ltd. job
CytoMed Therapeutics Pte. Ltd. stock
CytoMed Therapeutics Pte. Ltd. ownership
CytoMed Therapeutics Pte. Ltd. CEO
CytoMed Therapeutics Pte. Ltd. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.